+1,115.9%
MPWR vs MRNA
+915.3%
+200.6%
-51.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.9% | -3.4% | -0.5% | -3.6% |
| 7D | +16.8% | -12.1% | +28.9% | +18.2% |
| 30D | +11.9% | -1.3% | +13.2% | +11.9% |
| 3M | +2.2% | +250.9% | -248.7% | -16.0% |
| 6M | -15.5% | +343.0% | -358.5% | -34.0% |
| YTD | +54.2% | +657.4% | -603.3% | +8.7% |
| 1Y | +51.5% | +794.9% | -743.5% | +3.5% |
| 3Y | +180.2% | +218.1% | -37.9% | +115.6% |
| 5Y | +156.8% | -3.4% | +160.1% | +119.7% |
| All | +1,115.9% | +915.3% | +200.6% | +822.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling